Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials by Clowse, Megan E. B. et al.
ARTHRITIS & RHEUMATOLOGY
Vol. 69, No. 2, February 2017, pp 362–375
DOI 10.1002/art.39856
VC 2016 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc.
on behalf of the American College of Rheumatology. This is an open access article under
the terms of the Creative Commons Attribution-NonCommercial License, which permits
use, distribution and reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
Efficacy and Safety of Epratuzumab in Moderately
to Severely Active Systemic Lupus Erythematosus
Results From Two Phase III Randomized, Double-Blind,
Placebo-Controlled Trials
Megan E. B. Clowse,1 Daniel J. Wallace,2 Richard A. Furie,3 Michelle A. Petri,4
Marilyn C. Pike,5 Piotr Leszczynski,6 C. Michael Neuwelt,7 Kathryn Hobbs,8 Mauro Keiserman,9
Liliana Duca,10 Kenneth C. Kalunian,11 Catrinel Galateanu,12 Sabine Bongardt,13
Christian Stach,13 Carolyn Beaudot,14 Brian Kilgallen,14 and Caroline Gordon,15
on behalf of the EMBODY Investigator Group
Objective. Epratuzumab, a monoclonal antibody
that targets CD22, modulates B cell signaling without
substantial reductions in the number of B cells. The
aim of this study was to report the results of 2 phase III
multicenter randomized, double-blind, placebo-
controlled trials, the EMBODY 1 and EMBODY 2
trials, assessing the efficacy and safety of epratuzumab
in patients with moderately to severely active systemic
lupus erythematosus (SLE).
Methods. Patients met ‡4 of the American Col-
lege of Rheumatology revised classification criteria for
SLE, were positive for antinuclear antibodies and/or
anti–double-stranded DNA antibodies, had an SLE Dis-
ease Activity Index 2000 (SLEDAI-2K) score of ‡6
(increased disease activity), had British Isles Lupus
Assessment Group 2004 index (BILAG-2004) scores of
grade A (severe disease activity) in ‡1 body system or
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grade B (moderate disease activity) in ‡2 body systems
(in the mucocutaneous, musculoskeletal, or cardiorespi-
ratory domains), and were receiving standard therapy,
including mandatory treatment with corticosteroids (5–
60 mg/day). BILAG-2004 grade A scores in the renal and
central nervous system domains were excluded. Patients
were randomized 1:1:1 to receive either placebo,
epratuzumab 600 mg every week, or epratuzumab
1,200 mg every other week, with infusions delivered for
the first 4 weeks of each 12-week dosing cycle, for 4
cycles. Patients across all 3 treatment groups also con-
tinued with their standard therapy. The primary end
point was the response rate at week 48 according to the
BILAG-based Combined Lupus Assessment (BICLA)
definition, requiring improvement in the BILAG-2004
score, no worsening in the BILAG-2004 score, SLEDAI-
2K score, or physician’s global assessment of disease
activity, and no disallowed changes in concomitant medi-
cations. Patients who discontinued the study medication
were classified as nonresponders.
Results. In the EMBODY 1 and EMBODY 2 tri-
als of epratuzumab, 793 patients and 791 patients,
respectively, were randomized, 786 (99.1%) and 788
(99.6%), respectively, received study medication, and
528 (66.6%) and 533 (67.4%), respectively, completed
the study. There was no statistically significant differ-
ence in the primary end point between the groups, with
the week 48 BICLA response rates being similar
between the epratuzumab groups and the placebo group
(response rates ranging from 33.5% to 39.8%). No new
safety signals were identified.
Conclusion. In patients with moderate or
severely active SLE, treatment with epratuzumab1
standard therapy did not result in improvements in
response rates over that observed in the placebo1
standard therapy group.
Systemic lupus erythematosus (SLE) is a chronic
multisystem autoimmune disease (1) that most fre-
quently affects the musculoskeletal, mucocutaneous,
hematologic, and renal systems (2). The disease com-
monly follows a relapsing–remitting pattern, with flares
of high disease activity followed by temporary reduc-
tions in symptoms. Therapeutic options are limited.
Corticosteroids, often at high doses, form the corner-
stone of treatment. Their long-term use at high doses
(e.g., use of oral prednisone at a dosage of 0.5–1.0 mg/
kg/day) is associated with significant complications,
which may have a substantial impact on a patient’s health
and quality of life (3,4). Immunosuppressants and anti-
malarial drugs are frequently included in the patient’s
regimen, with the aim of reducing disease activity and
limiting the long-term organ damage arising either from
the disease itself or from corticosteroid use.
Recent advances in the understanding of SLE
pathogenesis and the central role of B cells in the patho-
logic processes of the disease have led to the advent of
biologic therapies for the management of lupus. One such
therapy is epratuzumab, a humanized monoclonal anti-
body of the IgG1 class that targets CD22 on B cells, per-
turbing the B cell receptor signaling complex and resulting
in the modulation of B cell activity without substantial
reductions in the number of peripheral B cells (5,6).
Epratuzumab has been evaluated as a therapy
for SLE in 12 sponsored clinical studies. In the 2 phase
II/III double-blind, placebo-controlled ALLEVIATE
studies (addressing the efficacy and safety of epra-
tuzumab in patients with moderate/severe flaring SLE),
the doses of epratuzumab used were based on body sur-
face area, and clinical outcomes were measured using
the British Isles Lupus Assessment Group (BILAG)
improvement response. Patients receiving a dose of
360 mg/m2 had improvements in the clinical signs and
symptoms of SLE (7) as well as improvements in quality
of life measures and reductions in their corticosteroid
dose (8). In the phase IIb EMBLEM study (addressing
the safety and efficacy of epratuzumab in patients with
serologically positive active SLE), fixed doses of
epratuzumab were investigated. This double-blind, pla-
cebo-controlled, dose-ranging and dose regimen–ranging
study utilized a composite response index, the BILAG-
based Combined Lupus Assessment (BICLA), which
emphasizes improvement based on changes in the
BILAG index, a measure of disease activity. The study
comprised 1 dosing cycle, with the study drug adminis-
tered over 4 weeks, and the primary end point was
assessed at week 12. A positive treatment effect, com-
pared to placebo, was seen in patients receiving
epratuzumab at a cumulative dose of 2,400 mg. This
dose was therefore carried forward into the phase III
studies, using the 2 different dosing regimens studied in
the phase IIb study (5,7,9).
In the present report, we present the results of
the 2 phase III multicenter, randomized, placebo-
controlled, double-blind EMBODY 1 and EMBODY 2
trials, which aimed to demonstrate the efficacy and
safety of epratuzumab in the treatment of patients with
moderately to severely active SLE.
PATIENTS AND METHODS
Patients. Inclusion criteria. Eligible patients were age
$18 years and had a diagnosis of moderately to severely active
SLE that fulfilled $4 of the 11 American College of Rheuma-
tology (ACR) revised criteria for SLE (10) (if patients were
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positive for a neurologic disorder, the diagnosis had to meet
$5 of 11 ACR criteria). All patients had, at a minimum, dis-
ease activity in the musculoskeletal, mucocutaneous, or cardio-
respiratory body systems, as defined by the 2004 version of the
BILAG index (BILAG-2004) (11). Patients were required to
have a BILAG-2004 grade A (severe disease activity) in $1 of
these body systems or a BILAG-2004 grade B (moderate dis-
ease activity) in $2 of these body systems. In addition, all
patients had to have an SLE Disease Activity Index 2000
(SLEDAI-2K) score of $6 (indicating increased disease activ-
ity) (12), and to be positive, at screening, for antinuclear anti-
bodies (ANAs; titer $1:80) and/or anti–double-stranded DNA
(anti-dsDNA) antibodies (defined as a positive result from
either a multiplex immunoassay or the Farr assay).
Patients must have been receiving corticosteroids at a
stable dosage of 5–60 mg/day (prednisone or equivalent) for at
least 5 days (61 day) prior to baseline. Antimalarials (hydro-
xychloroquine, chloroquine, or quinacrine) and immunosup-
pressants (azathioprine, mycophenolate mofetil, leflunomide,
or methotrexate) were not mandatory but were permitted,
whereas other immunosuppressants were excluded. Patients
treated with these agents must have received them at a stable
dose for at least 28 days (61 day) prior to baseline.
Exclusion criteria. Patients with severe lupus nephritis
or severe neuropsychiatric SLE at screening were excluded.
Thus, BILAG-2004 grade A scores in these body systems
(renal and neuropsychiatric domains) were not permitted
(with the exception of patients achieving a BILAG-2004 neu-
ropsychiatric grade A because of the presence of mononeuritis
[single or multiple] and/or polyneuropathy, provided that this
was not new or worsening at screening). Serum creatinine lev-
els of .2.5 mg/dl, a clinically significant increase in the serum
creatinine level within 4 weeks prior to screening, or protein-
uria levels of .3.5 gm/day were also exclusion criteria.
Other exclusions included patients with known anti-
phospholipid syndrome, those who were pregnant or breast-
feeding, those who had a profoundly immunosuppressed state,
and those with significant hematologic abnormalities, active
infections, a history of chronic infections, or a history of malig-
nancies or thromboembolic events. Significant hematologic
abnormalities (any laboratory finding of a hemoglobin level
,8.0 gm/dl, a white blood cell count ,2,000/mm3, an absolute
neutrophil count ,1,500/mm3, or a platelet count ,30,000/
mm3) were not allowed. Furthermore, patients were excluded if
they had received oral anticoagulants within 12 weeks prior to
screening, cyclophosphamide within 6 months prior to screen-
ing, or calcineurin inhibitors within 4 weeks prior to screening.
Previous use of biologic therapies was allowed, subject to an
appropriate protocol-defined washout period before screening.
Study design. The EMBODY 1 and EMBODY 2 tri-
als were identical phase III, multicenter, randomized, double-
blind, placebo-controlled studies, with the only difference
being the sites at which the studies took place (both studies
included sites in North America, Latin America, Western
Europe, Eastern Europe, and the Middle East and India;
EMBODY 1 additionally included the Pacific region [Australia]
and the Far East [Republic of Korea and Taiwan]; EMBODY
2 additionally included South Africa). All patients provided
their written informed consent, and the studies received
approval from the local institutional review boards/independent
ethics committees.
The primary end point was the responder rate at week
48, according to the BICLA composite end point (13), which
requires improvement from baseline in the BILAG-2004
score, with no worsening in the BILAG-2004 score, SLEDAI-
2K score, or physician’s global assessment of disease activity,
and no disallowed changes in concomitant medications (dis-
cussed in more detail below).
The studies consisted of a 2-week screening period,
followed by a 48-week double-blind treatment period, and a 4-
week safety follow-up (13 weeks for patients discontinuing
treatment prior to week 48). The sample size was selected to
provide 90% power to detect a 15% higher response, based on
the primary end point, in epratuzumab-treated patients com-
pared to placebo-treated patients (5,7).
In each study, 780 patients were planned for randomi-
zation, and patients were randomized 1:1:1 through an interac-
tive voice and web response system to 1 of 3 treatment arms:
placebo, epratuzumab 600 mg every week, or epratuzumab
1,200 mg every other week. Infusions were delivered over a 4-
week dosing period at the beginning of each 12-week treat-
ment cycle, i.e., 600-mg infusions of epratuzumab given at
weeks 0, 1, 2, and 3, or 1,200-mg infusions of epratuzumab
given at weeks 0 and 2 (with infusions of placebo at weeks 1
and 3, to maintain blinding), or infusions of placebo at weeks
0, 1, 2, and 3 (Figure 1). This dosing pattern was repeated
every 12 weeks for 4 cycles, with a final assessment at week 48.
Assessments were performed at baseline, and then at weeks 4,
8, and 12 of each cycle. Patients who either remained in the
study to completion at week 48 or withdrew at week 16 or
later, due to lack of efficacy, were allowed to enroll in the
open-label extension study (NCT01408576). The study drug
was given in conjunction with the patients’ existing standard
therapy (all concomitant medications are described below).
All patients must have been approved for randomiza-
tion by an external central reviewer to determine whether ade-
quate disease activity was present. Randomization was
stratified by geographic region (Eastern Europe, Western
Europe, Middle East and India, Far East, North America,
Latin America, and the Pacific) and by disease severity at
baseline. Disease severity was determined using the Systemic
Lupus International Collaborating Clinics/ACR Damage
Index (SDI) (14), categorized as follows: 1) an SDI score of 0
and a BILAG-2004 grade A in ,2 body systems, 2) an SDI
score of .0 or a BILAG-2004 grade A in $2 body systems, or
3) an SDI score of .0 and a BILAG-2004 grade A in $2 body
systems.
Concomitant medications. At baseline, all patients
must have been receiving oral corticosteroids at a dosage of 5–
60 mg/day (prednisone or equivalent). Between weeks 0 and 8,
temporary increases in the dose of corticosteroids up to a max-
imum of 25% above baseline levels were permitted at the dis-
cretion of the investigator. Patients were classified as
nonresponders if their corticosteroid dose remained above the
baseline level after week 8. From week 4, tapering of oral cor-
ticosteroids was encouraged, at a rate of 5 mg every 2 weeks to
a target dose of #7.5 mg/day. Corticosteroid dose changes
were to be avoided within 4 weeks of the week 24 and week 48
assessments.
Patients receiving immunosuppressants and/or antima-
larial agents had to continue their stable baseline dose
throughout the study, unless there was suspected toxicity.
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Patients changing their dose or starting a new immunosup-
pressant or antimalarial were considered nonresponders.
Study variables. The primary efficacy variable was
the improvement response at week 48 based on the BICLA
definition (13), which required all of the following criteria:
improvement in the BILAG-2004 score (improvement in all
BILAG-2004 grade A scores at study entry to grades B, C, or
D at follow-up; improvement in all BILAG-2004 grade B
scores at study entry to grades C or D at follow-up); no wors-
ening in the BILAG-2004 score (no new BILAG-2004 grade A
scores; no more than 1 new BILAG-2004 grade B score); no
worsening (no increase) in the SLEDAI-2K total score, as com-
pared to that at study entry; no worsening (,10-mm increase
on a 100-mm visual analog scale) in the physician’s global
assessment of disease activity, as compared to that at study
entry; and no disallowed changes in concomitant medications.
The BILAG-2004 body system scores and SLEDAI-2K data
were verified by a central review and adjudication committee to
ensure consistent application of the assessments.
Secondary efficacy variables were the BICLA response
rates at weeks 12, 24, and 36, and the change from baseline in
daily corticosteroid doses at weeks 24 and 48.
Exploratory efficacy variables included each compo-
nent of the BICLA composite end point, the BICLA response
at time points other than those included in the primary and
secondary end points, and changes from baseline in the
BILAG-2004 total score (scores were converted from grades
A, B, C, D, and E to scores of 12, 8, 1, 0, and 0, respectively)
(15), changes from baseline in the SLEDAI-2K total score,
changes from baseline in the patient’s and physician’s global
assessments of disease activity (on 100-mm visual analog
scales), and the average change from baseline in corticosteroid
dose (calculated as the time-weighted area under the curve
minus baseline, for baseline to week 48).
Analyses of patient-reported outcome measures in-
cluded the proportions of patients who achieved a minimal
clinically important difference (MCID) from baseline in the
36-item Short Form (SF-36) Health Survey physical and men-
tal component summary scores (defined as a $2.5-point
improvement) (16), mean changes from baseline in each of the
LupusQoL health-related quality of life domains (17), mean
changes from baseline in the Functional Assessment of
Chronic Illness Therapy–Fatigue (FACIT-F) scale (18), and
the proportions of patients achieving an MCID ($4-point
increase) in the FACIT-F scale.
Time to a new flare was also determined, with a new
flare defined as the development of a BILAG-2004 grade A in
$1 body system from a previous grade of B, C, D, or E at
baseline, or the development of a concurrent BILAG-2004
grade B in$2 body systems from a grade of C, D, or E at base-
line (systems flaring at baseline were not included). Flares
were based only on items that were new and were confirmed
by the central review and adjudication committee.
Pharmacodynamic and immunologic variables included
levels of CD191 B cells, CD31 T cells, CD191CD221 B cells,
immunoglobulins, autoantibodies (anti-dsDNA), extractable
nuclear antigen antibodies, and complement C3 and C4 proteins.
Statistical analysis. Efficacy variables were analyzed
using the full analysis set, consisting of randomized patients
who received at least one partial dose of study medication.
One of the EMBODY 1 study sites was found, by an audit, to
have failed to conduct the study in line with applicable
regulations, International Conference on Harmonisation/
Figure 1. A, Design of the EMBODY studies on efficacy and safety of epratuzumab monoclonal antibody (Emab) treatment in patients with
moderately to severely active systemic lupus erythematosus (SLE). B, Disposition of patients in the EMBODY 1 and EMBODY 2 trials. *5One
site in EMBODY 1 was removed from the study owing to safety concerns and a lack of compliance with the study protocol; all 45 patients
enrolled at this site were removed from the full analysis set, but retained in the safety set. QOW5 every other week; ST5 standard therapy;
QW5 every week; BICLA5British Isles Lupus Assessment Group–based Combined Lupus Assessment; PBO5 placebo.
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Good Clinical Practice Guidelines, and the study protocol,
and consequently all 45 patients enrolled at that site were
excluded from the full analysis set and the efficacy analyses.
These patients were retained in the safety set, to provide com-
plete safety data.
For determination of the primary end point, BICLA
response rates were calculated using logistic regression, with
patients who discontinued prior to week 48 or did not have a
week 48 assessment being classified as nonresponders. In
those cases in which single components of the BICLA
(BILAG-2004 scores, SLEDAI-2K scores, or physician’s
global assessment of disease activity) were missing, the value
was imputed from the previous visit value. Patients with
disallowed changes in concomitant medications were classified
as nonresponders from that time point forward.
In the primary analysis, P values for pairwise compari-
sons between each active treatment group and the placebo
group were generated using a logistic regression model,
including factors for pooled geographic region and disease
severity at baseline. The Hochberg method was used to adjust
for the comparison of the 2 doses of epratuzumab to placebo.
The response rate based on the primary variable was also ana-
lyzed in an exploratory manner for subgroups of patients,
including those defined by geographic region, body mass
index, baseline disease severity, lupus-associated laboratory
parameters, and concomitant medication use at baseline. Sub-
group analyses were not adjusted for multiplicity. Odds ratios
and corresponding 95% confidence intervals were calculated
for each epratuzumab treatment group compared to placebo,
using logistic regression models that included factors for treat-
ment, pooled region, and baseline disease status, as well as for
the subgroup being analyzed and the treatment-by-subgroup
interaction.
Five key secondary efficacy variables were tested for sta-
tistical significance according to a hierarchical testing procedure,
with Hochberg adjustment for multiplicity within each step of
the procedure. BICLA response rates at weeks 36, 24, and 12
were calculated and analyzed using the same methods as those
used for response rates at week 48. The key secondary end
points for the corticosteroid dose were ordered categorical end
points (patients were categorized according to their change in
daily corticosteroid dose, defined as a .50% decrease, 0–50%
decrease, no change, or an increase in dose or missing data),
analyzed using nonparametric rank analysis of covariance,
with missing values imputed as the worst possible outcome. All
other secondary and exploratory efficacy variables were summa-
rized using descriptive statistics, with missing data imputed using
last observation carried forward for continuous variables or
nonresponder imputation for dichotomous variables.
The SLE Responder Index (SRI) at week 48, which
was originally categorized as a $4-point (SRI-4), $6-point
(SRI-6), or $8-point (SRI-8) reduction in score on the Safety
of Estrogens in Lupus Erythematosus National Assessment
version of the SLEDAI (SELENA-SLEDAI) (19), were ana-
lyzed post hoc, with modifications from the original SRI end
point definition to include the variables used in the EMBODY
studies, i.e., improvement in the SLEDAI-2K scores, BILAG-
2004 scores, and the physician’s global assessment of disease
activity (instead of the SRI-4 calculated from the SELENA-
SLEDAI, the classic BILAG index, and the physician’s global
assessment of disease activity). To be considered a responder
in our SRI analyses, patients must have achieved all of the fol-
lowing: improvement in the SLEDAI-2K score of at least 4, 6,
or 8 points (SRI-4, SRI-6, and SRI-8, respectively) from study
entry; no worsening in the BILAG-2004 total score (no new
BILAG-2004 grade A scores, no more than 1 new BILAG-
2004 grade B score); no worsening (,10-mm increase on a
100-mm visual analog scale) in the physician’s global assess-
ment of disease activity, compared to that at study entry; and
no disallowed changes in concomitant medications at any time
point from baseline. Missing data were imputed using modi-
fied nonresponder imputation, as was used for the primary
end point.
Safety and immunologic variables were analyzed using
the safety set. These variables were summarized with descrip-
tive statistics.
RESULTS
Disposition of the patients and baseline charac-
teristics. In the EMBODY 1 trial, 1,257 patients were
screened, and 793 were randomized. In the EMBODY 2
trial, 1,194 patients were screened, and 791 were random-
ized. The majority of patients failed screening because
they were deemed ineligible on the basis of the inclusion
and exclusion criteria (367 of 464 screen failures in the
EMBODY 1 trial, and 315 of 403 screen failures in the
EMBODY 2 trial). Other reasons for exclusion included
occurrence of adverse events, loss to follow-up, and with-
drawal of consent during the screening period.
Overall, 265 patients (33.4%) in EMBODY 1
and 258 (32.6%) in EMBODY 2 discontinued from the
studies, most commonly due to lack of efficacy (112
patients in EMBODY 1, and 113 patients in EMBODY
2). One study site in the EMBODY 1 trial was removed
due to protocol violations, and all 45 patients random-
ized at that site were removed from the full analysis set.
Despite this, discontinuations were balanced across the
treatment groups and across the studies (range of dis-
continuations across groups 30.9–35.5% in EMBODY
1, and 30.8–34.7% in EMBODY 2) (Figure 1).
Patient characteristics at baseline were also bal-
anced between the 2 studies (Table 1). More than 90%
of patients were female, and the mean age was 42.1
years in EMBODY 1 and 41.0 years in EMBODY 2.
Time since diagnosis ranged from 0 years to 43 years,
with a median of 6.3 years in EMBODY 1 and 5.1 years
in EMBODY 2. The mean6SD daily corticosteroid
dosage was 11.26 8.8 mg/day in EMBODY 1 and
13.06 9.6 mg/day in EMBODY 2, with 45.1% of
patients in EMBODY 1 and 36.0% of patients in
EMBODY 2 receiving a dosage of #7.5 mg/day. The
proportion of patients receiving antimalarials at baseline
was slightly lower in EMBODY 2 than in EMBODY 1
(72.5% of patients in EMBODY 1 versus 63.6% of
patients in EMBODY 2).
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At baseline, 428 patients (57.8%) in EMBODY 1
and 466 patients (59.1%) in EMBODY 2 had a BILAG-
2004 grade A in $1 body system, while 371 patients
(50.1%) in EMBODY 1 and 411 patients (52.2%) in
EMBODY 2 had a BILAG-2004 grade B in $2 body
systems. Most patients had moderate-to-severe disease
activity in the musculoskeletal and mucocutaneous body
systems: for the musculoskeletal system, BILAG-2004
grades A or B were present in 92.2% of EMBODY 1
patients and 93.5% of EMBODY 2 patients; for the
mucocutaneous system, BILAG-2004 grades A or B
were present in 80.3% of EMBODY 1 patients and
83.0% of EMBODY 2 patients. Other patient character-
istics were also similar across treatment groups (Table 1).
Efficacy. The primary end point was not met in
either study. At week 48, improvements in disease activ-
ity, as measured by the BICLA response rates, occurred
in similar proportions of patients across treatment
groups; no significant differences were seen in the
proportion of responders between patients receiving
placebo1 standard therapy and those receiving either
dose of epratuzumab1 standard therapy (Figures 2A
and B). In the EMBODY 1 study, BICLA response
rates were 34.1% in the placebo1 standard therapy
group, 39.8% in the epratuzumab 1,200 mg every other
week1 standard therapy group (P5 0.175 versus
placebo), and 37.5% in the epratuzumab 600 mg
every week1 standard therapy group (P5 0.442 versus
placebo). In the EMBODY 2 study, BICLA response rates
were 33.5% in the placebo1 standard therapy group,
34.1% in the epratuzumab 1,200 mg every other
week1 standard therapy group (P5 0.899 versus placebo),
and 35.2% in the epratuzumab 600 mg every week1
standard therapy group (P5 0.716 versus placebo).
In the EMBODY 1 trial, 87 patients who received
placebo (34.9%) and 160 patients who received
epratuzumab (32.5%) did not achieve a treatment
response at week 48, which was attributed to early with-
drawal or missing data. Moreover, 54 patients in the pla-
cebo group (21.7%) and 134 patients in the epratuzumab
groups (27.2%) were classified as nonresponders as a
result of disallowed changes in concomitant medications
(predominantly, disallowed increases in the dose of cor-
ticosteroids; patients may have had more than one reason
for a nonresponse). In the EMBODY 2 trial, 84 patients
who received placebo (31.9%) and 166 patients who
received epratuzumab (31.6%) had missing data or with-
drew early from the study. Moreover, 60 patients in the
placebo group (22.7%) and 119 patients in the
epratuzumab groups (22.7%) had prohibited medication
changes (again, primarily increases in the dose of cor-
ticosteroids, with more than one reason for a nonre-
sponse being possible).
Rapid improvements from baseline were initially
seen in both the placebo group and the epratuzumab
dosing groups in both studies. At several time points,
Figure 2. BICLA responder rates by treatment group in the EMBODY 1 trial (A) and EMBODY 2 trial (B), and week 48 change from baseline in
daily corticosteroid (CS) dose in EMBODY 1 (C) and EMBODY 2 (D), as well as average change from baseline (E). See Figure 1 for other definitions.
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including weeks 12, 24, and 36, a trend toward improve-
ment in epratuzumab-treated patients over placebo was
seen, with nominally significant differences between the
placebo1 standard therapy group and the epratuzumab1
standard therapy treatment groups (i.e., P, 0.05 versus
placebo, without adjustment for multiple comparisons).
However, results were not consistent between the 2
studies, with the patients receiving epratuzumab
1,200 mg every other week1 standard therapy showing
a generally greater response in the EMBODY 1 trial,
and those receiving epratuzumab 600 mg every
week1 standard therapy showing a greater response in
the EMBODY 2 trial. Analyses of the primary efficacy
variable in predefined subgroups of subjects defined by
geographic region, ethnicity, immunologic parameters,
and concomitant medication usage at baseline yielded
results similar to those observed in the overall popula-
tion. Higher levels of treatment efficacy were not
observed in any of these subgroups (see Supplementary
Figures 1 and 2, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39856/abstract).
Various sensitivity analyses were performed to
assess the robustness of the study results, focusing on
study protocol adherence, handling of missing data, and
misstratification. The results of these sensitivity analyses
were generally consistent with the primary study results,
as was an analysis including only those patients complet-
ing the studies to week 48. Similarly, a post hoc analysis
using an adjusted BICLA definition of response, in
which the BILAG-2004 scores, SLEDAI-2K scores, and
physician’s global assessment of disease activity compo-
nents were retained but the rules regarding disallowed
changes in concomitant medications were omitted, did
not show any major difference in response rates
between the treatment groups.
Other key secondary end points also showed no
differences between the treatment groups. At weeks 48
and 24, similar proportions of patients in each treatment
group achieved reductions in the daily corticosteroid
dose (Figures 2C and D). At week 48, ;40% of
patients, irrespective of treatment group, had no change
in their corticosteroid dose relative to baseline (range
across groups 37.7–38.6% in EMBODY 1, and 35.6–
36.7% in EMBODY 2). Correspondingly, although the
average reductions in daily corticosteroid dose were
greater in EMBODY 2 than in EMBODY 1, within
each study, the average dose reductions from baseline
that patients were able to achieve were similar across
the treatment groups (Figure 2E).
Improvements were seen across a multitude of
exploratory end points, including improvements in the
BILAG-2004 scores, SLEDAI-2K scores, and physi-
cian’s and patient’s global assessments of disease activity
(see Supplementary Figures 3 and 4, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39856/abstract), as well as im-
provements in patient-reported outcomes such as the SF-
36 and FACIT-F scores (Table 2), and the LupusQoL
scores (see Supplementary Figure 5, http://onlinelibrary.
wiley.com/doi/10.1002/art.39856/abstract). However, in
all cases, improvements were comparable between the
placebo group and the epratuzumab-treated groups
(Table 2 and Supplementary Figures 3, 4, and 5).
New flares in disease activity (i.e., lower BILAG-
2004 scores at baseline developing to a new BILAG-
2004 grade A in $1 body system or a concurrent new
BILAG-2004 grade B in $2 body systems at follow-up,
among items recorded as new) occurred at a similar rate
across the treatment groups, both among all patients
irrespective of the treatment response and among those
patients who had previously achieved an improvement
in their BILAG-2004 score.
A post hoc analysis using the modified SRI
response criteria consistently failed to detect any differ-
ences in response between the placebo group and the
epratuzumab treatment groups, at either the SRI-4,
SRI-6, or SRI-8 levels of improvement in SLEDAI
scores.
Immunologic response. Consistent with the
findings of previous studies (5), a median reduction of
30–40% in peripheral B cell levels was seen in
epratuzumab-treated patients, but not in placebo-
treated patients (Table 3). These changes occurred rap-
idly, with reductions in peripheral B cell levels of ;20%
in the first 4 weeks of treatment, followed by a gradual
decline in B cell numbers up to week 48. Levels of T
cells, IgA, and IgG were stable throughout the studies,
with only minor fluctuations from baseline and no con-
sistent trends. Levels of IgM decreased by ;20% from
baseline in epratuzumab-treated patients in both studies
(Table 3).
Safety. In both studies, the incidence of adverse
events was comparable between the placebo and
epratuzumab treatment groups (Table 4). Treatment-
emergent adverse events occurred in 79.9–88.0% of
patients across all treatment groups, the most common
being upper respiratory tract infections, urinary tract
infections, headache, and nausea. Serious adverse
events occurred in 17.0–18.9% of patients (Table 4).
The only serious adverse event that occurred in $2% of
patients was worsening of SLE, reported in 1.1–2.7% of
patients across the treatment groups.
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There were 5 deaths in the EMBODY 1 trial and
4 deaths in the EMBODY 2 trial (4 occurring in the
placebo1 standard therapy group and 5 occurring in
the epratuzumab treatment groups). Deaths in the
patients who received placebo were attributable to
pneumonia (Australia), lupus myocarditis (India), SLE
(Ukraine), and pneumothorax (Hungary). Deaths in the
epratuzumab-treated patients were attributable to sepsis
(2 patients [1 in the US, 1 in Brazil]), pulmonary embo-
lism (Bulgaria), acute renal failure and septic shock
(Taiwan), and pneumonia and pulmonary alveolar hem-
orrhage (Brazil).
DISCUSSION
In both of these phase III trials, the observed
immunologic effects of epratuzumab treatment were
as expected for this agent, based on previous observa-
tions (5). Treatment of patients with moderately to
severely active SLE with epratuzumab led to reductions
in the levels of CD22, with the number of B cells in
the peripheral blood decreasing by ;30–40% and IgM
levels decreasing by 20%. However, treatment with
epratuzumab in conjunction with standard therapy did
not result in improved efficacy outcomes at week 48 as
compared to treatment with placebo in conjunction with
standard therapy; neither of these phase III studies
achieved statistically significant differences in the pri-
mary end point. Across a multiplicity of end points,
including clinical parameters, corticosteroid use, and
patient-reported outcomes, no increased benefit from
the addition of epratuzumab treatment to standard care
was detected. The planned and exploratory analyses
suggested that this was not a failure of the BICLA com-
posite end point or the study design, but rather a failure
of the study drug and/or the regimens tested.
The treatment differences observed in these
studies were far lower than those seen in the phase IIb
EMBLEM study, in which 21% of patients who received
placebo and 40–45% of patients who received 1,200 mg
epratuzumab every other week or 600 mg epratuzumab
every week achieved a response at week 12 (compared
to response rates in the present study of 34% of patients
who received placebo and 34–40% of patients who
received epratuzumab). Several factors can be hypothe-
sized to have influenced the analysis of the primary end
point at week 48 in the EMBODY studies.
First, the rate of discontinuation was higher and
earlier than expected across all treatment groups,
mainly due to a perceived lack of efficacy as assessed by
the investigator and a desire to enter the open-label
extension study. Approximately one-third of patients
discontinued the study prior to week 48, and therefore
were classified as nonresponders. Discontinuations
from the studies were generally low from week 0 to
week 16, but increased at weeks 20 and 24, which were
the first visits at which patients were allowed to enroll in
the open-label study. Some separation of improvement
with epratuzumab as compared to placebo was visible in
both studies at time points prior to week 48 (although it
should be noted that differences were not consistent
between the studies). However, sensitivity analyses con-
ducted using alternate methods of imputation for miss-
ing data were consistent with those of the primary
analysis, and did not detect any significant differences in
BICLA response rates between the placebo group and
the epratuzumab treatment groups at week 48.
Second, evident in nearly all of the end points
examined were the high placebo response rates in these
trials. This in itself may be informative, suggesting that
with ongoing monitoring and regular attention from
their care teams, patients are likely to experience
greater improvements in their disease activity than
would otherwise be the case. This phenomenon has
been described previously in the TICORA study (Tight
Control for Rheumatoid Arthritis), in which a program
of intensive outpatient management resulted in
improvements in disease when compared to routine
care (20). Although further studies are needed to for-
mally explore this notion, the data herein suggest that
the same may be true in other chronic diseases such as
SLE. Although the doses of corticosteroids used initially
were not as high as some previous trials, it is notable
that ;40% of patients did not reduce their dosage of
corticosteroids during the EMBODY trials, and another
40% increased their dosage or had missing data.
The kinetics of response to epratuzumab are
likely to be complex, and its mechanism of action is not
fully understood, but based on the phase IIb EMBLEM
trial data, the doses chosen were expected to be effica-
cious (5,6). It is possible that the doses or dosing
regimens adopted in these trials were not optimal. In
the phase IIb EMBLEM trial, it was noted that the
dose-response followed a bell-shaped curve, with the
highest dose of medication eliciting a smaller clinical
response than more moderate doses (5). The data pres-
ented herein do not formally exclude the possibility of a
subgroup of responders, but none of the analyses con-
ducted were able to identify this subset, although mean
B cell numbers and IgM levels were reduced in
epratuzumab-treated patients.
Clinical trials of biologic agents in SLE have gen-
erally been met with failure. To date, only one agent,
belimumab, which inhibits the activity of soluble B
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lymphocyte stimulator, is licensed for use in active and
autoantibody-positive SLE in the US and Europe (21),
having met its primary end points in 2 phase III trials
(22,23). Even in these trials, there was a higher than
expected placebo response, and one of the trials only
just marginally showed a significant difference in favor
of belimumab (22,23). The failure of the EMBODY
studies, as well as studies of other agents that have suf-
fered similar fates (24–28), highlights the tremendous
challenges of drug development research in SLE.
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APPENDIX A: THE EMBODY TRIAL
INVESTIGATOR GROUPS
Members of the EMBODY 1 Investigator Group include the
following: in Eastern Europe, A. Batalov, M. Bojinca, R. Djerassi,
L. Duca, P. Horak, Z. Kolarov, R. Milasiene, D. Monova, K. Otsa, M.
Pileckyte, T. Popova, F. Radulescu, R. Rashkov, S. Rednic, M. Repin,
R. Stoilov, D. Tegzova, N. Vezikova, P. Vitek, and C. Zainea; in the Far
East, H. Baek, Y. Chen, Y. Chiu, C. Cho, C. Chou, J. Choe, C. Huang,
Y. Kang, S. Kang, N. Lai, S. Lee, W. Park, S. Shim, C. Suh, and
W. Yoo; in Latin America, H. Avila Armengol, F. Avila Zapata, M.
Barreto Santiago, F. Cavalcanti, W. Chahade, L. Costallat, M.
Keiserman, J. Orozco Alcala, C. Ramos Remus, and L. Roimicher; in
the Middle East and India, M. Abu-Shakra, V. Agarwal, N. Agmon-
Levin, J. Kadel, Y. Levy, D. Mevorach, D. Paran, T. Reitblat, I. Rosner,
V. Shobha, Z. Sthoeger, and D. Zisman; in North America, K. Ayesu,
S. Berney, J. Box, H. Busch, J. Buyon, J. Carter, J. Chi, M. Clowse, R.
Collins, K. Dao, I. Diab, A. Dikranian, M. El-Shahawy, N. Gaylis,
J. Grossman, E. Halpert, J. Huff, W. Jarjour, A. Kao, R. Katz,
A. Kennedy, M. Khan, A. Kivitz, M. Kohen, T. Lawrence-Ford,
J. Lawson, M. Levesque, M. Lowenstein, A. Majjhoo, R. Mcarthur, D.
McLain, J. Merrill, A. Murillo, S. Neucks, G. Niemer, G. Noaiseh, C.
Parker, C. Pantojas, D. Pattanaik, M. Petri, P. Pickrell, J. Reveille, A.
Roman-Miranda, N. Rothfield, A. Sankoorikal, M. Sayers, A. Singhal,
A. Snyder, C. Striebich, Q. Vo, J. von Feldt, D. Wallace, M. Wasko,
and C. Young; in the Pacific, S. Adelstein, S. Hall, G. Littlejohn, D.
Nicholls, and M. Suranyi; in Western Europe, Z. Amoura, B. Bannert,
F. Behrens, L. Carreno Perez, K. Chakravarty, F. Diaz Gonzales, K.
Davies, A. Doria, P. Emery, A. Fernandez-Nebro, M. Govoni, E.
Hachulla, B. Hellmich, F. Houssiau, M. Malaise, J. Margaux, Y.
Maugars, S. Mu~noz-Fernandez, F. Navarro, J. Ordi-Ros, R. Pellerito, J.
Pena-Sagredo, E. Roussou, R. E. Schmidt, E. Ucar-Angulo, J-F.
Viallard, R. Westhovens, M. Worm, and C. S. Yee.
Members of the EMBODY 2 Investigator Group include the
following: in Africa, S. Nayiager, H. Reuter, and C. Spargo; in Eastern
Europe, B. Bazela, M. Brzosko, D. Chudzik, B. Gasztonyi, P. Geher, R.
Ionescu, S. Jeka, L. Kemeny, E. Kiss, P. Kotyla, L. Kovacs, V.
Kovalenko, E. Kucharz, B. Kwiatkowska, P. Leszczynski, E. Levchenko,
G. Lysenko, M. Majdan, C. Mihailov, S. Nalotov, M. Nedelciu,
M. Pavel, T. Raskina, B. Rebrov, E. Rezus, T. Semen, S. Smakotina, M.
Stanislavchuk, M. Stanislav, I. Szombati, G. Szucs, G. Udrea, J. Zajdel,
and A. Zon-Giebel; in Latin America, R. Bonfiglioli, R. Bustamante, E.
Klumb, G. Medrano Ramirez, C. Neiva, M. Olguin, J. Reyes Gonzaga,
A. Scotton, S. Sicsik Ayala, and A. Ximenes; in the Middle East and
India, R. Sharma and C. Srikantiah; in North America, J. Aelion, C.
Aranow, M. Baker, A. Chadha, J. Chao, W. Chatham, A. Chow, C.
Clay, S. Cohen-Gadol, D. Conaway, J. Denburg, A. Escalante, L.
Espinoza, J. Fiechtner, I. Fortin, A. Fraser, R. Furie, D. Gladman, D.
Goddard, M. Goldberg, R. Gonzalez-Rivera, J. Gorman, R. Griffin,
D. Haaland, D. Halter, A. Hemaiden, K. Hobbs, V. Joshi, S. Lim, K.
Kalunian, G. Karpouzas, M. Khraishi, R. Lafyatis, S. Lee, R. Lidman,
C. Lue, M. Mohan, P. Mease, C. Mehta, W. Mizutani, A. Nami, J.
Nascimento, C. Neuwelt, J. Pappas, J. Pope, A. Porges, G. Roane, D.
Rosenberg, S. Ross, C. Saadeh, C. Scoville, Y. Sherrer, M. Solomon, W.
Surbeck, G. Valenzuela, and P. Waller; in Western Europe, R. Alten,
C. Baerwald, B. Bienvenu, S. Bombardieri, J. Braun, L. Dival, G.
Espinosa, I. Figueroa Fernandez, J. Gomez-Reino, C. Gordon, F.
Hiepe, N. Hopkinson, D. Isenberg, A. Jacobi, C. Jorgensen, V. Le
Guern, C. Paul, J. M. Pego-Reigosa, J. Rodriguez Heredia, A. Rubbert-
Roth, M. Sabbadini, J. Schroeder, A. Schwarting, W. Spieler, G.
Valesini, J. Wollenhaupt, A. Zea Mendoza, and C. Zouboulis.
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